Oral pravastatin prolongs survival time of scrapie-infected mice

Journal of General Virology

Volumn 90, Issue 7, 2009, Pages 1775-1780

  Vetrugno, Vito ^a   Di Bari, Michele Angelo ^a   Nonno, Romolo ^a   Puopolo, Maria ^a   D'Agostino, Claudia ^a   Pirisinu, Laura ^a   Pocchiari, Maurizio ^a   Agrimi, Umberto ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; PRAVASTATIN; PRION PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SOLUBILITY; FEMALE; HYDROPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCRAPIE; SURVIVAL TIME; WEIGHT GAIN; ANIMAL; SURVIVAL; TIME;

MURINAE; MUS; SUID HERPESVIRUS 1;

ANIMALS; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; PRAVASTATIN; SCRAPIE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 67849106793     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.009936-0     Document Type: Article

References (49)

1. Aguzzi, A., Sigurdson, C. & Heikenwaelder, M. (2008). Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 3, 11-40.
2. Araki, K., Masaki, T., Katsuragi, I., Kakuma, T. & Yoshimatsu, H. (2008). Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 16, 2068-2073.
3. Bate, C., Salmona, M., Diomede, L. & Williams, A. (2004). Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 279, 14983-14990.
4. Burns, M. P., Igbavboa, U., Wang, L., Wood, W. G. & Duff, K. (2006). Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromolecular Med 8, 319-328.
5. Carp, R. I., Callahan, S. M., Sersen, E. A. & Moretz, R. C. (1984). Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent-mouse strain combination. Intervirology 21, 61-69.
6. Chauhan, N. B., Siegel, G. J. & Feinstein, D. L. (2004). Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res 29, 1897-1911.
7. Chen, D., Steele, A. D., Hutter, G., Bruno, J., Govindarajan, A., Easlon, E., Lin, S., Aguzzi, A., Lindquist, S. & Guarente, L. (2008). The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol 43, 1086-1093.
8. Cheng, X., Maher, J., Chen, C. & Klaassen, C. D. (2005). Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos 33, 1062-1073.
9. Debatin, L., Streffer, J., Geissen, M., Matschke, J., Aguzzi, A. & Glatzel, M. (2008). Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5, 347-354.
10. Di Bari, M. A., Chianini, F., Vaccari, G., Esposito, E., Conte, M., Eaton, S. L., Hamilton, S., Finlayson, J., Steele, P. J. & other authors (2008). The bank vole (Myodes glareolus) as a sensitive bioassay for sheep scrapie. J Gen Virol 89, 2975-2985.
11. Evers, R. & Chu, X. (2008). Role of the murine organic anion transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 74, 309-311.
12. Gilch, S., Kehler, C. & Schatzl, H. M. (2006). Prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci 31, 346-353.
13. Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C. & Breteler, M. M. B. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
14. Haviv, Y., Avrahami, D., Ovadia, H., Ben-Hur, T., Gabizon, R. & Sharon, R. (2008). Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch Neurol 65, 762-775.
15. Johnson-Anuna, L. N., Eckert, G. P., Keller, J. H., Igbavboa, U., Franke, C., Fechner, T., Schubert-Zsilavecz, M., Karas, M., Müller, W. E. & Wood, W. G. (2005). Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312, 786-793.
16. Kempster, S., Bate, C. & Williams, A. (2007). Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 18, 479-482.
17. Kikuchi, R., Kusuhara, H., Abe, T., Endou, H. & Sugiyama, Y. (2004). Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J Pharmacol Exp Ther 311, 1147-1153.
18. Kirsch, C., Eckert, G. P. & Mueller, W. E. (2003). Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65, 843-856.
19. Kivisto, K. T. & Niemi, M. (2007). Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24, 239-247.
20. Liao, J. K. & Laufs, U. (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45, 89-118.
21. Lütjohann, D., Stroick, M., Bertsch, T., Kühl, S., Lindenthal, B., Thelen, K., Andersson, U., Björkhem, I., von Bergmann, K. & Fassbender, K. (2004). High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69, 431-438.
22. Michel, V. & Bakovic, M. (2007). Lipid rafts in health and disease. Biol Cell 99, 129-140.
23. Mok, S. W. F., Thelen, K. M., Riemer, C., Bamme, T., Gultner, S., Lutjohann, D. & Baier, M. (2006). Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun 348, 697-702.
24. Neuvonen, P. J., Backman, J. T. & Niemi, M. (2008). Pharmacokinetic comparison of the potential over-the-counter statins, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47, 463-474.
25. Nezasa, K., Higaki, K., Takeuchi, M., Nakano, M. & Koike, M. (2003). Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33, 379-388.
26. Nonno, R., Di Bari, M. A., Cardone, F., Vaccari, G., Fazzi, P., Dell'Omo, G., Cartoni, C., Ingrosso, L., Boyle, A. & other authors (2006). Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2, e12.
27. Parkin, E. T., Watt, N. T., Hussain, I., Eckman, E. A., Eckman, C. B., Manson, J. C., Baybutt, H. N., Turner, A. J. & Hooper, N. M. (2007). Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 104, 11062-11067.
28. Rajanikant, G. K., Zemke, D., Kassab, M. & Majid, A. (2007). The therapeutic potential of statins in neurological disorders. Curr Med Chem 14, 103-112.
29. Reid, P. C., Urano, Y., Kodama, T. & Hamakubo, T. (2007). Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11, 383-392.
30. Reiss, A. B. & Wirkowski, E. (2007). Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs 67, 2111-2120.
31. Schachter, M. (2005). Chemical, pharmacokinetic and pharmaco-dynamic properties of statins: an update. Fundam Clin Pharmacol 19, 117-125.
32. Seithel, A., Glaeser, H., Fromm, M. F. & König, J. (2008). The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 4, 51-64.
33. Simes, J., Furberg, C. D., Braunwald, E., Davis, B. R., Ford, I., Tonkin, A. & Shepherd, J. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 23, 207-215.
34. Simons, K. & Ehehalt, R. (2002). Cholesterol, lipid rafts, and disease. J Clin Invest 110, 597-603.
35. Sirvent, P., Mercier, J. & Lacampagne, A. (2008). New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8, 333-338.
36. Smith, P. F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., Kari, P. H. & MacDonald, J. S. (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 257, 1225-1235.
37. Sparrow, C. P., Burton, C. A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., Rosa, R., Hermanowski-Vosatka, A., Wang, P. R. & other authors (2001). Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21, 115-121.
38. Stewart, L. A., Rydzewska, L. H., Keogh, G. F. & Knight, R. S. (2008). Systematic review of therapeutic interventions in human prion disease. Neurology 70, 1272-1281.
39. Switzer, J. A. & Hess, D. C. (2006). Statins in stroke: prevention, protection and recovery. Expert Rev Neurother 6, 195-202.
40. Takagi, T., Matsuda, M., Abe, M., Kobayashi, H., Fukuhara, A., Komuro, R., Kihara, S., Caslake, M. J., McMahon, A. & other authors (2008). Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 196, 114-121.
41. Taraboulos, A., Scott, M., Semenov, A., Avraham, D., Laszlo, L. & Prusiner, S. B. (1995). Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 129, 121-132.
42. Taylor, D. R. & Hooper, N. M. (2007). Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin Cell Dev Biol 18, 638-648.
43. Thelen, K. M., Rentsch, K. M., Gutteck, U., Heverin, M., Olin, M., Andersson, U., von Eckardstein, A., Björkhem, I. & Lütjohann, D. (2006). Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 316, 1146-1152.
44. Trevitt, C. R. & Collinge, J. (2006). A systematic review of prion therapeutics in experimental models. Brain 129, 2241-2265.
45. Trinkl, A., Vosko, M. R., Wunderlich, N., Dichgans, M. & Hamann, G. F. (2006). Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusion. Eur J Neurosci 24, 520-526.
46. Tseng, M. Y., Hutchinson, P. J., Turner, C. L., Czosnyka, M., Richards, H., Pickard, J. D. & Kirkpatrick, P. J. (2007). Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled trial. J Neurosurg 107, 1092-1100.
47. Vetrugno, V., Cardinale, A., Filesi, I., Mattei, S., Sy, M. S., Pocchiari, M. & Biocca, S. (2005). KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem Biophys Res Commun 338, 1791-1797.
48. Vey, M., Pilkuhn, S., Wille, H., Nixon, R., DeArmond, S. J., Smart, E. J., Anderson, R. G., Taraboulos, A. & Prusiner, S. B. (1996). Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci U S A 93, 14945-14949.
49. White, H. D., Simes, R. J., Anderson, N. E., Hankey, G. J., Watson, J., Hunt, D., Colquhoun, D. M., Glasziou, P., MacMahon, S. & other authors (2000). Pravastatin therapy and the risk of stroke. N Engl J Med 343, 317-326.